Mangement pos hirstism

Management of positional hirsutism involves first differentiating it from other causes of excess hair growth and assessing for underlying hormonal or endocrine abnormalities.

Positional hirsutism, characterized by localized, isolated areas of terminal hair growth in androgen-dependent regions, may not always require extensive investigation if the hirsutism score is normal and there are no other signs of hyperandrogenism. In such cases, initial management can focus on cosmetic and symptomatic approaches, including advice on hair removal techniques such as shaving, waxing, electrolysis, and laser treatment.

If the hirsutism is mild, localized, and without evidence of a hyperandrogenic disorder, biochemical testing may be unnecessary unless hair growth progresses despite treatment NICE CKS.

For facial hirsutism specifically, topical eflornithine cream can be offered to women aged 19 years and older as a non-invasive treatment to reduce hair growth NICE CKS.

In premenopausal women with hirsutism suggestive of androgen excess or abnormal hirsutism scores, assessment of serum total testosterone is recommended, and if markedly elevated (>4 nmol/L), referral to endocrinology is advised NICE CKS. If an underlying disorder such as polycystic ovary syndrome (PCOS) or adrenal/ovarian neoplasms is suspected, further specialist evaluation and treatment including anti-androgens (cyproterone acetate, spironolactone, finasteride) or insulin-sensitizing agents might be necessary Buzney et al. 2014.

Weight loss advice should be provided for overweight or obese women, as reduction in adiposity can lower insulin resistance and hyperandrogenemia, which are common drivers of hirsutism, especially in PCOS-related cases NICE CKS; Wang et al. 2025.

Combined oral contraceptives (COCs) may be offered to reduce androgen levels and subsequent hair growth in women without contraindications NICE CKS.

Recent literature also highlights adjunctive nutritional supplements such as inositol and probiotics, which have been shown to improve insulin sensitivity and reduce androgen levels in PCOS, potentially helping hirsutism management though evidence specific to positional hirsutism is limited Wang et al. 2025.

If hirsutism progresses or fails to respond to at least a 6-month trial of conservative management, specialist referral is warranted for further endocrine evaluation and potential pharmacological treatment NICE CKS.